2024
Impact of COVID-19 Treatment on Real-World Outcomes in Inflammatory Bowel Disease
Sahyoun L, Fetene J, McMillan C, Protiva P, Al Bawardy B, Gaidos J, Proctor D. Impact of COVID-19 Treatment on Real-World Outcomes in Inflammatory Bowel Disease. Digestive Diseases And Sciences 2024, 69: 1654-1660. PMID: 38466459, DOI: 10.1007/s10620-024-08355-3.Peer-Reviewed Original ResearchSevere COVID-19 infectionInflammatory bowel diseaseCOVID-19 infectionIBD flareIBD therapyCOVID-19 treatmentSingle-center retrospective study of adult patientsMethodsA single-center retrospective studyAdvanced therapiesRetrospective study of adult patientsBowel diseaseStudy of adult patientsInflammatory bowel disease therapyDevelopment of severe COVID-19 infectionSevere COVID-19Acute COVID-19Corticosteroid useNo significant differenceNo therapyAdult patientsSupplemental oxygenPrimary outcomeSecondary outcomesTherapyCorticosteroids
2022
A Practical Approach to IBD Care in the Pregnant Patient
Sahyoun L, Gaidos J. A Practical Approach to IBD Care in the Pregnant Patient. Current Gastroenterology Reports 2022, 24: 201-209. PMID: 36422770, DOI: 10.1007/s11894-022-00856-3.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseManagement of IBDPrior inflammatory bowel diseaseNew IBD therapiesNew biologic agentsPouch-anal anastomosisSimilar success ratesPurpose of ReviewAsIBD careIBD patientsIBD therapyActive diseaseDisease remissionFetal outcomesIBD treatmentPregnant patientsIBD populationPreconception counselingPregnancy outcomesBiologic agentsBowel diseasePeripartum periodMedication safetyPrevious guidelinesPregnancy
2021
THE SAFETY, TOLERABILITY, AND EFFECTIVENESS OF BIOLOGICS/SMALL MOLECULE THERAPY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND CIRRHOSIS
Li M, Khan S, Proctor D, Gaidos J, Al-Bawardy B. THE SAFETY, TOLERABILITY, AND EFFECTIVENESS OF BIOLOGICS/SMALL MOLECULE THERAPY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND CIRRHOSIS. Inflammatory Bowel Diseases 2021, 27: s45-s46. DOI: 10.1093/ibd/izaa347.110.Peer-Reviewed Original ResearchInflammatory bowel diseaseBiologic agentsAdverse eventsSmall molecule therapiesClinical remissionMucosal healingBowel diseaseConcomitant cirrhosisConcomitant corticosteroid therapyDifferent biologic agentsPrimary sclerosing cholangitisQuarter of patientsCohort of patientsEffectiveness of biologicsSmall molecule agentsConcomitant thiopurinesCorticosteroid therapyIBD patientsIBD therapyCertolizumab pegolSclerosing cholangitisAdult patientsBiologic therapyInfusion reactionsSecondary outcomes
2017
Managing IBD Therapies in Pregnancy
Gaidos JK, Kane SV. Managing IBD Therapies in Pregnancy. Current Treatment Options In Gastroenterology 2017, 15: 71-83. PMID: 28181180, DOI: 10.1007/s11938-017-0123-5.Peer-Reviewed Original ResearchDisease remissionAnti-tumor necrosis factor agentsInflammatory bowel disease treatmentNecrosis factor agentsIBD medicationsIBD therapyDisease activityFactor agentsQuiescent diseaseBiologic agentsBowel diseaseHealthy pregnancyTreatment regimenMedication adherenceCombination therapyPatient's desireCurrent evidenceLower riskMost womenPregnancyAdverse effectsLess evidenceDisease treatmentRemissionBreastfeeding